Regulatory agencies are increasing the pressure on pharmaceutical companies to detect drug interactions in the early stages of clinical research. Anaxomics helps you to proactively identify them using a predictive systems biology approach, reducing the risk of unexpected events in clinical stages.
Drug-drug interactions occur when the physiological effects of one drug are modified by the presence of another drug. Adverse drug-drug interactions are a major cause of concern, especially in elderly poly-medicated individuals, because they can provoke dangerous adverse effects or undermine therapeutic efficacy. On the other hand, synergistic or additive interactions can be also exploited clinically to increase the beneficial effect of a combinatorial therapy.
In the light of these considerations, regulatory agencies are increasing the pressure on pharmaceutical companies to detect drug interactions as early as possible. For this reason, Anaxomics is offering a systems biology approach to identify drug interactions at the target level that are not directly evident.
Systems Biology predicts unsuspected drug interactions
Drug interactions are complex in nature, because they may involve multiple protein effectors and biochemical pathways at the same time. Systems Biology, which takes into consideration the whole complexity of living beings, provides unique solutions to elucidate these interactions.
- Mechanistic explanations for drug interactions
- Evaluation of the entire protein human map
- Inclusion of disease, target and other biological data
Our Therapeutic Performance Mapping System (TPMS) proprietary technology creates protein maps that take into account both the polypharmacological effect of drugs and the signal propagation across the network. Supply us with a drug or a combination of drugs and TPMS will identify compounds that give rise to:
- Interactions producing serious adverse events
- Interactions lowering drug efficacy
- Interactions increasing drug efficacy